Clinical trial · Interventional
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anthracyclines (e.g. Doxorubicin) are an important and highly effective chemotherapeutic. They are used in various tumor entities and are established for breast cancer treatment. The most significant prognostic side effect is cardiotoxicity, which occurs in up to 50 patients. Female gender must be considered an independent risk factor for the incidence and severity of associated heart failure. The aim of this study is to demonstrate that dose-dependent anthracycline-induced cardiotoxicity has a measurable effect on T2 mapping on MRI. The second aim is to demonstrate if the combination of diastolic strain (echo and MRI) and T2 mapping can detect earlier anthracycline-induced myocardial damage than via the established method of the echocardiographic measurement of LV-EF and the conventional quantification of diastolic function.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Myocardial Damage | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiac MRI and echocardiography, laboratory parameters | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- reduction of the left ventricular ejection fraction (LV-EF) by 10% to under 50%
- timeFrame
- after 12 months
- description
- volumetric determination of LV-EF
Secondary outcomes (1)
- measure
- reduction of the left ventricular global longitudinal strain (GLS) by over 15%
- timeFrame
- after 12 months
- description
- determination of GLS via strain analysis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Planned therapy with an anthracycline and at least 1 year follow up * \>18 years of age * written informed consent Exclusion Criteria: * prior cardiovascular disease * diabetes mellitus * previous therapy with anthracyclines
References
Publications (1)
- DERIVEDVoss F, Nienhaus F, Pietrucha S, Ruckhaberle E, Fehm T, Melz T, Cramer M, Haberkorn SM, Flogel U, Westenfeld R, Scheiber D, Jung C, Kelm M, Polzin A, Bonner F. Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer. Cardiooncology. 2024 Jul 16;10(1):43. doi: 10.1186/s40959-024-00244-y. PMID 39014463